Last time we wrote about Novan (NOVN) we suggested you should buy because they may be coming up with an inhalent based nitric oxide treatment for the coronavirus illness known as COVID-19.
Novan is a clinical development-stage biotechnology company focused on leveraging nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal and immunomodulatory mechanisms of action to treat a range of diseases with significant unmet needs.
Novan (NOVN) Stock Outlook
Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Their ability to harness nitric oxide and its multiple mechanisms of action has enabled them to create a platform with the potential to generate differentiated product candidates.
The two key components of Novan’s nitric oxide platform are their proprietary Nitricil technology, which drives the creation of new chemical entities, or NCEs, and our formulation science, both of which they use to tune product candidates for specific indications.
The ability to deploy nitric oxide in a solid form, on demand and in localized formulations allows Novan the potential to improve patient outcomes in a variety of diseases. The company have advanced strategic development programs in the field of dermatology, while also further expanding the platform into women’s health and gastroenterological, or GI, therapeutic areas.
This decision was based on the connection between the multi-factorial pathologies of diseases in these areas and the demonstrable anti-microbial, anti-viral and anti-inflammatory properties of Novan’s nitric oxide technology. The goal is to create the world’s leading macro-molecular nitric
oxide-based science, technology, and clinical translation company that delivers safe and efficacious therapies for patients.
Novan has clinical-stage dermatology drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208) and anti-inflammatory (SB414) mechanisms of action.
Novan also recently introduced SB207 as a possible product candidate for additional anti-viral programs such as coronavirus or covid-19. The company has also conducted preclinical work on NCEs and formulations for the treatment of human papilloma virus, or HPV, related illnesses in the women’s health field (WH504 and WH602) and inflammatory diseases in the GI field.
